Want to see TSE:ARCH full AI Analyst Report?
ARCH Stock Chart & Stats
C$1.03
-C$0.02(-2.30%)
At close: 4:00 PM EDT
C$1.03
-C$0.02(-2.30%)
Day’s Range― - ―
52-Week RangeC$0.39 - C$1.66
Previous CloseN/A
Volume14.22K
Average Volume (3M)64.99K
Market Cap
C$60.46M
Enterprise ValueC$56.39
Total Cash (Recent Filing)C$2.91K
Total Debt (Recent Filing)C$2.73M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding67,933,290
10 Day Avg. Volume52,007
30 Day Avg. Volume64,989
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineA focused therapeutic strategy targets serious acute injuries linked to inflammation and ischemia-reperfusion, including acute kidney injury. Concentrating development resources on this defined medical need may support clearer clinical priorities and a coherent long-term product strategy.
Core LSALT Peptide CandidateLSALT peptide provides a specific lead asset around which Arch can organize clinical development and future commercialization efforts. Its intended endothelial-protection mechanism gives the company a differentiated therapeutic rationale, although clinical validation remains necessary.
Improving Cash UsageCash consumption has decreased compared with earlier periods, which indicates some progress in controlling operating outflows. If maintained, lower burn could extend available financial resources and give management more time to advance development before requiring additional funding.
Bears Say
No Current Revenue And Persistent LossesThe absence of trailing revenue and the record of recurring annual losses show that the business has not yet reached commercial validation or operating profitability. Continued losses may restrict internal investment capacity and leave future progress dependent on successful development and financing.
Stressed CapitalizationNegative equity combined with meaningful debt and a very thin asset base leaves little balance-sheet cushion against setbacks. This capitalization can limit financial flexibility, increase dependence on external funding, and make it harder to sustain development through prolonged clinical timelines.
Operations Remain Cash-flow NegativeEven after the improvement in cash usage, operations continue to consume cash and free cash flow remains approximately aligned with reported losses. Without internally generated funding, Arch may need continued capital support to maintain its programs and corporate activities.
Arch Biopartners News
ARCH FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.66 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is C$60.46M.
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Feb 02, 2027 which is in 137 days.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on Aug 31, 2026. The company reported -C$0.007 earnings per share for the quarter.
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 67,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -C$0.007 in its last earnings report. Following the earnings report the stock price went down -1.942%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arch Biopartners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arch Biopartners
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Technical Analysis
Satellos Bioscience
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―